Medical ethics committee approves of anti-Covid drug Lagevrio

Ljubljana – Slovenia’s national medical ethics committee has no reservations towards Lagevrio, a medicine also known as molnupiravir. The committee maintains that the drug brings significant progress in fighting the coronavirus epidemic, as it prevents a severe course of Covid-19 or death. The European Medicines Agency (EMA) recommended the drug for coronavirus treatment on 19 November even if it is not yet registered. The oral anti-viral drug, being developed by Merck Sharp & Dohme in collaboration with Ridgeback Biotherapeutics, is intended for the treatment of Covid-19 in adults. The EMA…

For FREE further reading please JUST enter your email address

I allow to collect my email data for analytics and email campaign